Highlights
- Market Cap
- $103.34M
- Enterprise Value
- $83.40M
- EPS (TTM)
- -$1.16
- EBITDA (TTM)
- -$38.11M
- Year Range
- $1.00 - $6.91
- Target Price
- $7.75
- ROA (TTM)
- -56.78%
- ROE (TTM)
- -66.29%
Share Price Chart
Loading graphics...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
The chart shows the growth of an initial investment of $10,000 in AN2 Therapeutics Inc, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Loading graphics...
Returns By Period
AN2 Therapeutics Inc (ANTX) has returned 200.00% so far this year and 151.47% over the past 12 months.
AN2 Therapeutics Inc
- 1D
- -1.16%
- 1M
- 210.91%
- YTD
- 200.00%
- 6M
- 169.29%
- 1Y
- 151.47%
- 3Y*
- -29.76%
- 5Y*
- —
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- 2.91%
- 1M
- -5.09%
- YTD
- -4.63%
- 6M
- -2.39%
- 1Y
- 16.33%
- 3Y*
- 16.69%
- 5Y*
- 10.18%
- 10Y*
- 12.16%
Monthly Returns
Based on dividend-adjusted daily data since Mar 25, 2022, ANTX's average daily return is +0.15%, while the average monthly return is +4.28%. At this rate, your investment would double in approximately 1.4 years.
Historically, 41% of months were positive and 59% were negative. The best month was Mar 2026 with a return of +210.9%, while the worst month was Feb 2024 at -84.6%. The longest winning streak lasted 3 consecutive months, and the longest losing streak was 4 months.
On a daily basis, ANTX closed higher 45% of trading days. The best single day was Mar 9, 2026 with a return of +84.2%, while the worst single day was Feb 12, 2024 at -74.5%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -0.88% | -2.65% | 210.91% | 200.00% | |||||||||
| 2025 | -17.39% | -0.00% | 19.30% | -8.82% | -14.52% | -0.00% | -0.00% | 3.77% | 15.45% | -3.15% | -11.38% | 4.59% | -17.39% |
| 2024 | -5.81% | -84.56% | 9.06% | -26.15% | -17.08% | 8.04% | 18.60% | -55.69% | -5.31% | 0.93% | 54.63% | -17.37% | -93.27% |
| 2023 | 27.60% | -7.24% | -12.50% | -20.47% | -28.54% | 51.52% | -4.47% | 85.22% | 6.91% | -10.32% | 21.84% | 16.62% | 115.01% |
| 2022 | -2.14% | 3.72% | -4.03% | -48.33% | 10.45% | 100.23% | 1.40% | -17.03% | -30.86% | -4.41% | -38.12% |
Benchmark Metrics
AN2 Therapeutics Inc has an annualized alpha of 33.91%, beta of 0.80, and R² of 0.01 versus S&P 500 Index. Calculated based on daily prices since March 28, 2022.
- This stock tended to rise when S&P 500 Index fell (downside capture of -335.46%), but participation in market rallies was also limited (-123.43%) — a profile typical of counter-cyclical assets.
- R² of 0.01 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 33.91%
- Beta
- 0.80
- R²
- 0.01
- Upside Capture
- -123.43%
- Downside Capture
- -335.46%
Return for Risk
Risk / Return Rank
ANTX ranks 88 for risk / return — in the top 88% of stocks on our site. This means strong returns relative to risk — exactly what professional investors look for. Well-suited for investors who want to maximize return per unit of risk.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for AN2 Therapeutics Inc (ANTX) and compare them to a chosen benchmark (S&P 500 Index).
| ANTX | Benchmark | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | 1.19 | 0.90 | +0.29 |
Sortino ratioReturn per unit of downside risk | 3.74 | 1.39 | +2.36 |
Omega ratioGain probability vs. loss probability | 1.46 | 1.21 | +0.25 |
Calmar ratioReturn relative to maximum drawdown | 3.91 | 1.40 | +2.51 |
Martin ratioReturn relative to average drawdown | 7.88 | 6.61 | +1.27 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Explore ANTX risk-adjusted metrics in detail
Dive deeper into individual metrics with historical trends, benchmark comparisons, and performance across different time periods.
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading graphics...
Worst Drawdowns
The table below displays the maximum drawdowns of the AN2 Therapeutics Inc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the AN2 Therapeutics Inc was 95.60%, occurring on Aug 16, 2024. The portfolio has not yet recovered.
The current AN2 Therapeutics Inc drawdown is 84.66%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -95.6% | Aug 16, 2022 | 504 | Aug 16, 2024 | — | — | — |
| -59.56% | May 9, 2022 | 58 | Aug 1, 2022 | 9 | Aug 12, 2022 | 67 |
| -13.49% | Apr 5, 2022 | 5 | Apr 11, 2022 | 12 | Apr 28, 2022 | 17 |
| -2.6% | Mar 28, 2022 | 3 | Mar 30, 2022 | 2 | Apr 1, 2022 | 5 |
| -1.82% | Apr 29, 2022 | 1 | Apr 29, 2022 | 1 | May 2, 2022 | 2 |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading graphics...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of AN2 Therapeutics Inc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how AN2 Therapeutics Inc is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for ANTX in comparison with other companies in the Biotechnology industry. Currently, ANTX has a P/B value of 1.9. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |